Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Healthy returns: Japan’s assault on old-age di ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today, whereby the following resolutions were made. Adoption of the income statement ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

Algernon to Acquire NoBrainer - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology ...

Leqembi can cause side effects that range from mild to serious. More common side effects include headache and infusion reactions. If side effects from Leqembi become difficult to tolerate, talk ...